Apotex Inc.

Apotex Inc. is a Canadian-based global pharmaceutical company, recognized as the largest producer of generic drugs in Canada. Founded in 1974, its core mission is to improve everyday access to affordable, high-quality, and innovative medicines and health products for millions of people worldwide. The company's headquarters are located in Toronto, Ontario, Canada.

Apotex's extensive portfolio includes over 300 generic pharmaceuticals available in approximately 4,000 dosages and formats, addressing a wide range of health conditions such as cancer, diabetes, high cholesterol, glaucoma, infections, and blood pressure. Beyond generic medications, the company is actively involved in research and development, the manufacturing of fine chemicals, non-prescription and private-label medicines, and disposable plastics for medical use. Apotex also has a significant presence in the biosimilar market and serves over 115 countries globally, with key operations in Canada, the United States, Mexico, and India.

In March 2026, Jeff Watson was appointed President and CEO, marking his return to the leadership role he previously held from 2018 to 2023. This change followed Allan Oberman's decision to step down as CEO and resume a board member position. Apotex, a portfolio company of SK Capital Partners since its acquisition in April 2023, has been in the news recently for several key developments. In May 2026, Health Canada approved Apo-Semaglutide Injection, a generic equivalent of Ozempic®, making Apotex the first Canadian-based pharmaceutical company to achieve this. The company also announced a strategic transaction in April 2026 with Cumberland Pharmaceuticals to integrate their U.S. branded businesses and received Health Canada approval for DENOZA™, a Denosumab Biosimilar. Furthermore, there are ongoing reports from early 2026 about a potential initial public offering (IPO) in the first half of the year, aiming to raise between $750 million and $1 billion, though SK Capital Partners is expected to retain control.